Glimpse Group grants director 174,368 stock options

Glimpse Group, Inc. director Tamar Elkeles received a grant of stock options covering 174,368 shares of common stock on July 10, 2026, with an exercise price of $0.77 per share and expiration on July 10, 2036.

Rhea-AI Filing Summary

Glimpse Group, Inc. director Tamar Elkeles received a grant of stock options covering 174,368 shares of common stock on July 10, 2026, with an exercise price of $0.77 per share and expiration on July 10, 2036. The grant vests in equal monthly installments over one year from the grant date. Elkeles also holds earlier option grants for 145,000, 37,500 and 20,000 shares at exercise prices of $0.69, $2.25 and $2.50, expiring between 2034 and 2036, some of which are already fully vested.

Insider Trade Summary

Grant/Award: 174,368 shares

Grant/Award 4 txns

Insider Elkeles Tamar

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	174,368	$0.00	$0.00
holding	Stock Option (Right to Buy) F2	--	--	--
holding	Stock Option (Right to Buy) F3	--	--	--
holding	Stock Option (Right to Buy) F3	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 376,868 contracts for 202,500 underlying shares (Direct)

Footnotes (3)

1. F1. This option vests in equal monthly installments over a one-year period commencing on the grant date.
2. F2. This option vested with respect to 60,422 shares on 5/31/2026, and the remainder vests in equal monthly increments from 6/30/2026 through 12/31/2026.
3. F3. This option has fully vested as of the date of this report.

Key Figures

New option grant: 174,368 shares at $0.77 per share Partially vesting option: 145,000 underlying shares at $0.69 Fully vested option 1: 37,500 underlying shares at $2.25 +2 more

5 metrics

New option grant 174,368 shares at $0.77 per share Stock Option (Right to Buy) granted 2026-07-10, expiring 2036-07-10

Partially vesting option 145,000 underlying shares at $0.69 Option expiring 2036-05-01; 60,422 shares vested 5/31/2026, remainder vests monthly through 12/31/2026

Fully vested option 1 37,500 underlying shares at $2.25 Stock option expiring 2035-01-01, fully vested as of this report

Fully vested option 2 20,000 underlying shares at $2.50 Stock option expiring 2034-05-01, fully vested as of this report

Vesting period of new grant 1 year New option vests in equal monthly installments over a one-year period from grant date

Key Terms

Stock Option (Right to Buy), exercise price, vests in equal monthly installments, fully vested

4 terms

Stock Option (Right to Buy) financial

"Reported as a Stock Option (Right to Buy) exercisable into common stock."

exercise price financial

"The new grant carries an exercise price of $0.77 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in equal monthly installments financial

"This option vests in equal monthly installments over a one-year period."

fully vested financial

"This option has fully vested as of the date of this report."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GGRP director Tamar Elkeles report?

Tamar Elkeles reported a grant of stock options for 174,368 Glimpse Group common shares on July 10, 2026, at an exercise price of $0.77 per share, expiring July 10, 2036, vesting in equal monthly installments over one year.

How many Glimpse Group (GGRP) options were granted and at what exercise price?

The filing shows a grant of 174,368 stock options, each exercisable into one Glimpse Group common share at an exercise price of $0.77, with the option term running until July 10, 2036, subject to monthly vesting over one year.

What is the vesting schedule for Tamar Elkeles’s new GGRP stock option grant?

The new option grant for 174,368 shares vests in equal monthly installments over a one-year period starting from the July 10, 2026 grant date, meaning portions become exercisable each month during that year.

What other Glimpse Group (GGRP) stock options does Tamar Elkeles hold?

Elkeles also holds options over 145,000 shares at $0.69 expiring May 1, 2036, plus 37,500 shares at $2.25 and 20,000 shares at $2.50 expiring January 1, 2035 and May 1, 2034, with the latter two fully vested.

Are Tamar Elkeles’s GGRP insider transactions under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked as affirming a trading plan, and the footnotes do not describe any 10b5-1 plan, so these option positions are not identified as plan-based in this report.

Do any of Tamar Elkeles’s existing GGRP options continue vesting after this filing?

Yes. An option for 145,000 shares at $0.69 had 60,422 shares vested as of May 31, 2026, with the remaining portion vesting in equal monthly increments from June 30 through December 31, 2026, according to the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 04:33 PM Accepted by SEC EDGAR 08/06/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elkeles Tamar

(Last) (First) (Middle)

15 WEST 38TH ST

12TH FLOOR

(Street)

NEW YORK NEW YORK 10018

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Glimpse Group, Inc. [ GGRP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.77	07/10/2026		A		174,368		(1)	07/10/2036	Common Stock	174,368	$0	174,368	D
Stock Option (Right to Buy)	$0.69							(2)	05/01/2036	Common Stock	145,000		145,000	D
Stock Option (Right to Buy)	$2.25							(3)	01/01/2035	Common Stock	37,500		37,500	D
Stock Option (Right to Buy)	$2.5							(3)	05/01/2034	Common Stock	20,000		20,000	D

Explanation of Responses:

1. This option vests in equal monthly installments over a one-year period commencing on the grant date.

2. This option vested with respect to 60,422 shares on 5/31/2026, and the remainder vests in equal monthly increments from 6/30/2026 through 12/31/2026.

3. This option has fully vested as of the date of this report.

	/s/ William J. Keneally, Attorney-in-Fact for Tamar Elkeles	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)